Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis - ScienceDirect

View PDF

Journal of Infection

Volume 85, Issue 4, October 2022, Pages e122-e124

Journal of Infection

https://doi.org/10.1016/j.jinf.2022.05.044 Get rights and content

Highlights

•
All studies compared the impact of regdanvimab on clinical outcomes.
•
A total of 7 articles comprising 3333 adult patients with COVID-19 were included in the analysis.
•
Outcomes suggested that regdanvimab administration reduces the risk of disease aggravation and death among COVID-19 patients.

Keywords

COVID-19

Regdanvimab

Mortality

SARS-CoV-2

Cited by (0)

¹: These authors contributed equally to this work.

© 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.